{"id":53053,"date":"2023-01-18T19:03:20","date_gmt":"2023-01-18T18:03:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/"},"modified":"2023-01-18T19:03:20","modified_gmt":"2023-01-18T18:03:20","slug":"hanger-announces-ceo-transition-plan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/","title":{"rendered":"Hanger Announces CEO Transition Plan"},"content":{"rendered":"
\n

\nVinit Asar to retire effective May 1, 2023; Pete Stoy named as successor<\/i>\n<\/p>\n

<\/a><\/p>\n

AUSTIN, Texas–(BUSINESS WIRE)–Hanger, Inc., a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced Chairman and Chief Executive Officer (CEO) Vinit Asar will retire from the role of CEO effective May 1, 2023 after more than a decade in the position. In line with a multi-year succession plan, Hanger\u2019s Chief Operating Officer (COO) Pete Stoy has been named President and COO, and will assume the role of CEO upon Asar\u2019s retirement, in addition to serving on Hanger\u2019s Board of Directors. At that time, Asar\u2019s role will transition to Executive Chairman of Hanger\u2019s Board, where he will assist with strategic initiatives, including mergers and acquisitions, and provide support for Stoy and the Board as needed.\n<\/p>\n

\n\u201cIt has been my absolute honor to serve as Hanger\u2019s CEO over the past eleven years,\u201d shared Asar. \u201cEach day I have been fueled by the passion our team brings to fulfilling our shared purpose of empowering human potential together, and I\u2019m eternally grateful for what we have achieved together throughout these years.\u201d Asar continued: \u201cAfter making the decision to retire, I have been able to put in place a succession plan over the past couple of years to ensure I leave Hanger in excellent hands. Pete\u2019s background, style, and experiences have more than adequately prepared him to be a fabulous leader for Hanger, and I know the future is bright with Pete at the helm.\u201d\n<\/p>\n

\nAsar joined Hanger as Executive Vice President and Chief Growth Officer in Dec. 2008, and served as Hanger\u2019s President and COO from Sept. 2011 \u2013 May 2012 before taking the reigns as CEO. During his tenure, he was instrumental in stabilizing the company\u2019s infrastructure to create an environment with a strong foundation to prepare Hanger to grow from a $700M company to a $1.4B company. He also set the industry standard on how companies should view and focus on diversity and inclusion across the spectrum, and was instrumental in establishing the Hanger Institute for Clinical Research and Education to focus on advancing clinical practice and improving outcomes for those who need life-enhancing O&P care.\n<\/p>\n

\n\u201cVinit has made an indelible impact on Hanger throughout his storied tenure,\u201d stated Stoy. \u201cHe will leave behind an impressive legacy that will continue to live as part of Hanger\u2019s extensive history, and we applaud and thank him for his exceptional leadership.\u201d Stoy continued: \u201cI personally would like to express my sincere gratitude for our close collaboration and partnership as I have been preparing to serve as Hanger\u2019s next CEO.\u201d\n<\/p>\n

\nStoy has more than 20 years of healthcare experience with leadership in large, complex organizations, and holds a designation as a Fellow of the American College of Healthcare Executives (FACHE). Prior to joining Hanger as COO in Nov. 2020 where he has made an immediate and significant impact, Stoy served as East Region President for the healthcare business of Sodexo. Prior to that role, Stoy served in leadership positions at McKesson where he oversaw the multi-billion dollar McKesson U.S. Pharmaceutical Health System segment, and also held senior positions in hospital sales and pharmaceutical distribution during his 13-year employment at Cardinal Health.\n<\/p>\n

\nAbout Hanger, Inc. \u2013 <\/b>Headquartered in Austin, Texas, Hanger, Inc. provides comprehensive, outcomes-based orthotic and prosthetic (O&P) services through its Patient Care segment, with approximately 875 Hanger Clinic locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. Rooted in 160 years of clinical excellence and innovation, Hanger is a purpose-driven company with a vision to lead the O&P markets by providing superior patient care, outcomes, services and value, aimed at empowering human potential. For more information on Hanger, visit corporate.hanger.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nKrisita Burket, Hanger, Inc.
\n
904-239-4627
\n
kburket@hanger.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Vinit Asar to retire effective May 1, 2023; Pete Stoy named as successor AUSTIN, Texas–(BUSINESS WIRE)–Hanger, Inc., a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced Chairman and Chief Executive Officer (CEO) Vinit Asar will retire from the role of CEO effective May 1, 2023 after more than a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53053","6":"format-standard","7":"category-industry"},"yoast_head":"\nHanger Announces CEO Transition Plan - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hanger Announces CEO Transition Plan - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Vinit Asar to retire effective May 1, 2023; Pete Stoy named as successor AUSTIN, Texas–(BUSINESS WIRE)–Hanger, Inc., a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced Chairman and Chief Executive Officer (CEO) Vinit Asar will retire from the role of CEO effective May 1, 2023 after more than a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-18T18:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230118005708\/en\/690736\/21\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Hanger Announces CEO Transition Plan\",\"datePublished\":\"2023-01-18T18:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/\"},\"wordCount\":656,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005708\\\/en\\\/690736\\\/21\\\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/\",\"name\":\"Hanger Announces CEO Transition Plan - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005708\\\/en\\\/690736\\\/21\\\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg\",\"datePublished\":\"2023-01-18T18:03:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005708\\\/en\\\/690736\\\/21\\\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230118005708\\\/en\\\/690736\\\/21\\\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/hanger-announces-ceo-transition-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hanger Announces CEO Transition Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hanger Announces CEO Transition Plan - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/","og_locale":"en_US","og_type":"article","og_title":"Hanger Announces CEO Transition Plan - Pharma Trend","og_description":"Vinit Asar to retire effective May 1, 2023; Pete Stoy named as successor AUSTIN, Texas–(BUSINESS WIRE)–Hanger, Inc., a leading provider of orthotic and prosthetic (O&P) patient care services and solutions, today announced Chairman and Chief Executive Officer (CEO) Vinit Asar will retire from the role of CEO effective May 1, 2023 after more than a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-18T18:03:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230118005708\/en\/690736\/21\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Hanger Announces CEO Transition Plan","datePublished":"2023-01-18T18:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/"},"wordCount":656,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230118005708\/en\/690736\/21\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/","url":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/","name":"Hanger Announces CEO Transition Plan - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230118005708\/en\/690736\/21\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg","datePublished":"2023-01-18T18:03:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230118005708\/en\/690736\/21\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230118005708\/en\/690736\/21\/HNGR_LOGO_Tag_4C_reg_%283%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/hanger-announces-ceo-transition-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Hanger Announces CEO Transition Plan"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53053"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53053\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}